Alzheimer's disease (AD) is the most common cause of dementia and, despite decades of effort, there is no effective treatment. In the last decade, many association studies have identified genetic markers that are associated with AD status. Two of these studies suggest that an epistatic interaction between variants rs1049296 in the Transferrin (TF) gene and rs1800562 in the Homeostatic Iron Regulator (HFE) gene, commonly known as "the hemochromatosis gene", is in genetic association with AD. TF and HFE are involved in the transport and regulation of iron in the brain, and disrupting these processes exacerbates AD pathology through increased neurodegeneration and oxidative stress. However, by using a significantly larger dataset from the Alzheimer's Disease Genetics Consortium (ADGC), we fail to detect an association between TF rs1049296 or HFE rs1800562 with AD risk (TF rs1049296 p=0.38 and HFE rs1800562 p=0.40 ). In addition, logistic regression with an interaction term and a Synergy Factor Analysis (SFA) both failed to detect epistasis between TF rs1049296 and HFE rs1800562 (SF=0.94; p=0.48) in AD cases. Each of these analyses had sufficient statistical power (Power>0.99), suggesting that previously-reported associations may be the result of more complex epistatic interactions, genetic heterogeneity, or were false-positive associations due to limited sample sizes.
Introduction
Alzheimer's disease (AD) is the most common cause of dementia and inflicts an estimated 24 to 35 million people worldwide, with incidences predicted to increase dramatically as the population ages ("2018 Alzheimer's disease facts and figures," 2018). Although decades of research have been spent investigating the causes and architecture of this neurodegenerative disease, it still inflicts an estimated 5.7 million people in the United States alone. This number is projected to increase to 13.8 million by mid-century ("2018 Alzheimer's disease facts and figures," 2018). Association studies have accurately identified single-nucleotide polymorphisms (SNPs) associated with AD (D. Harold et al., 2009; Denise Harold et al., 2009; Hollingworth et al., 2011; J.-C. Lambert et al., 2009; J. C. Lambert et al., 2013; Seshadri et al., 2010; Shen et al., 2015; Shuai et al., 2015; Yan et al., 2015) . However, these genetic loci account for only a fraction of AD heritability, (Ridge, Mukherjee, Crane, Kauwe, & Alzheimer's Disease Genetics, 2013) suggesting that much of AD's unexplained genetic make-up may be due to epistasis (Bullock et al., 2013; Combarros, Cortina-Borja, Smith, & Lehmann, 2009; M. T. Ebbert et al., 2014; Infante et al., 2004) . Epistasis occurs when multiple genes interact to create a single phenotype (Cordell, 2002) . These kinds of synergetic relationships play a critical role in the etiology of complex diseases, yet remain vastly understudied in AD pathology ("2018 Alzheimer's disease facts and figures," 2018; M. T. W. Ebbert, Ridge, & Kauwe, 2015; Raghavan & Tosto, 2017) .
The Transferrin (TF) gene and the Homeostatic Iron Regulator (HFE) gene, commonly known as "the hemochromatosis gene", have been reported to show epistasis and play a role in the development of AD (Robson et al., 2004; Tisato et al., 2018) . TFs are a group of non-heme ironbinding glycoproteins found in fluids and cells of vertebrates. The main role of TF is to maintain iron homeostasis in the body (Gkouvatsos, Papanikolaou, & Pantopoulos, 2012) . In the brain, TF interacts with the Amyloid Precursor Protein (APP) (Belaidi et al., 2018) and tau (Jahshan, Esteves-Villanueva, & Martic-Milne, 2016) , two of the major protein families implicated in AD pathology. Since iron is essential for oxygen transport, its mis-regulation in the brain can lead to oxidative stress and neurodegeneration (Dias, Junn, & Mouradian, 2013; Matak et al., 2016; Yarjanli, Ghaedi, Esmaeili, Rahgozar, & Zarrabi, 2017) . HFE encodes for a transmembrane glycoprotein that binds to a TF receptor, subsequently regulating iron in the cell (Bennett, Lebron, & Bjorkman, 2000; Feder et al., 1996; Lebron et al., 1998) . Mutations in HFE are associated with neurodegenerative diseases through increasing neuroinflammation and production of free radicals in the brain (Andersen, Johnsen, & Moos, 2014; Lull & Block, 2010 ). In addition, other studies suggest that TF and HFE are involved in the transport and regulation of iron in the brain, and disrupting these processes potentially affects AD pathology through increased neurodegeneration and oxidative stress (Ali-Rahmani, Schengrund, & Connor, 2014; Lehmann et al., 2006) . Robson et al. (2004) suggested that epistasis between TF variant rs1049296 and HFE variant rs1800562 is associated with AD. Although neither SNP alone was a risk factor for AD, the presence of both alleles resulted in a five times greater risk of developing AD. (Robson et al., 2004) . Since the sample size for that study was relatively small (191 cases and 269 controls), a replication of these findings on a slightly larger dataset (1,161 cases and 1,342 controls) was
Results
The nonparametric logistic regression analysis using ADGC as one cohort demonstrated that when testing the main effects, neither TF rs1049296 nor HFE rs1800562 was associated with AD risk (TF rs1049296 p=0.38; HFE rs1800562 p=0.40). The logistic regression analyses including an interaction term for the two variants also failed to show significant association (p=0.23). Similarly, the SFA analysis did not find epistasis between TF rs1049296 and HFE rs1800562 (SF=0.94; p=0.48).
We performed logistic regression on all 30 individual cohorts (see Figure 1 ). We detected a significant epistatic association between the interaction term and AD status in the ACT cohort (p=0.038) and a suggested association in the ADC1 cohort (p=0.063). In addition, the individual effect of HFE rs1800562 shows a suggested association with AD status in the ADC6 (p=0.099), WHICAP (p=0.052), ADC4 (p=0.076), and ROSMAP (p=0.094) cohorts. Furthermore, logistic regression for the individual effect of TF rs1049296 determined a significant association with AD status in the WASHU cohort (p=0.016). However, none of these associations remained significant after a Bonferroni correction for multiple tests.
In addition, chi-squared analyses between terms and AD status demonstrated a non-significant likelihood for any single term or interaction. The odds ratio for rs1049269 was 0.97 with a 95% confidence interval (CI) between 0.92 and 1.03, while rs1800562 had an odds ratio of 1.06 with a CI of 0.98 to 1.15, and the interaction term had an odds ratio of 0.99 with a CI of 0.86 to 1.14. The odds ratios and confidence intervals for main effects and the interaction in each cohort are displayed in Figure 2 .
Discussion
We failed to detect evidence of epistasis between TF rs1049296 and HFE rs1800562 as a risk for AD in the ADGC dataset. These findings do not support the conclusions drawn in the previous reports by Robson et al. (2004) and Kauwe et al. (Kauwe et al., 2010) . The cause for this variability among studies could be a result of genetic heterogeneity, the complex nature of epistasis, or false positives in these previous studies due to limited sample size.
Although recent literature suggests that much of the unidentified genetic makeup of AD is due to epistasis (Bullock et al., 2013; Combarros et al., 2009; M. T. Ebbert et al., 2014; Infante et al., 2004; Mez, 2016) , the complex nature of these gene-gene interactions makes it difficult for them to be accurately measured and defined (Gilbert-Diamond & Moore, 2011; Kouyos, Silander, & Bonhoeffer, 2007; Urbanowicz, Kiralis, Fisher, & Moore, 2012) . Models for epistatic interactions are challenging to create because the models require large datasets to analyze combinations of variables simultaneously (Moore & Williams, 2009) . When an insufficient number of samples are used, results have poor statistical power, which leads to frequent false negatives in gene-gene interaction studies. Likewise, the numerous comparisons required to assess epistasis may generate false positive findings (Mackay & Moore, 2014) . Inadequate sample size can also result in false positives and is identified through statistical power analyses (Christley, 2010) . The experiments performed by Robson et al. (2004) and Kauwe et al. (Kauwe et al., 2010) used datasets with much fewer individuals than the dataset used in this manuscript, and consequently have lower statistical power than our analysis. Although Kauwe et al. (2010) appeared to have sufficient power for their study (0.95), it is still possible that their results were false positive findings. Current research suggests a troubling phenomenon known as the "winner's curse," which occurs when the estimated effect of an association is inflated compared to the true genetic effect and the effects later measured in follow-up studies (Huang, Ritchie, Brozynska, & Inouye, 2018; Palmer & Pe'er, 2017) . The level of power necessary to accurately detect epistasis is currently unknown, and as such, replication studies are a necessary part of validating epistasis. As our results show, even studies that appear to have sufficient power, such as Kauwe et al. (2010) , should be re-evaluated when larger datasets become available.
Heterogeneity in the genetic causes of AD is certainly present (Mez, 2016) , and further erodes power to detect statistical epistasis. Finally, even when statistical evidence for epistasis is detected, it does not necessarily indicate the presence of a physical biological interaction between the implicated proteins (M. T. W. Ebbert et al., 2015) . Statistical patterns can be a product of a variety of underlying mechanisms. Therefore, the complexity of biological and statistical epistasis could also account for disparities in replication studies. Increasing sample sizes gives us better statistical power. Likewise, increasing the amount of multidimensionalomics data will help us focus our efforts on specific candidate interactions. We anticipate that as more multidimensional -omics data become available, our ability to understand the role of epistasis in AD risk will improve and help in the development of novel approaches to prevent and treat the disease. 
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